OPTIMI HEALTH CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.35 CAD | +2.94% |
|
+9.38% | +42.86% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2022 | 0.08 0.11 6.73 | Sales 2023 | 0.18 0.25 15.11 | Capitalization | 16.1M 22.12M 1.34B |
|---|---|---|---|---|---|
| Net income 2022 | -7M -9.61M -584M | Net income 2023 | -5M -6.87M -417M | EV / Sales 2022 | 28,94,22,204 x |
| Net cash position 2022 | 1.73M 2.38M 144M | Net Debt 2023 | 362K 498K 30.24M | EV / Sales 2023 | 9,09,20,762 x |
| P/E ratio 2022 |
-3.29
x | P/E ratio 2023 |
-3.1
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 82.45% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +2.94% | ||
| 1 week | +9.38% | ||
| Current month | +9.38% | ||
| 1 month | +45.83% | ||
| 3 months | +12.90% | ||
| 6 months | +112.12% | ||
| Current year | +42.86% |
1 week
0.31
0.38
1 month
0.250.38
Current year
0.210.58
1 year
0.150.58
3 years
0.150.84
5 years
0.151.10
10 years
0.151.10
| Managers | Title | Age | Since |
|---|---|---|---|
Dane Stevens
FOU | Founder | 34 | 27/20/27 |
William Ciprick
CEO | Chief Executive Officer | 56 | 07/21/07 |
Jacob Safarik
DFI | Director of Finance/CFO | 36 | 06/20/06 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 45 | 07/20/07 | |
John Wilson
FOU | Founder | 34 | 27/20/27 |
Bryan Safarik
COO | Chief Operating Officer | 39 | 06/20/06 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 07/24/07 | 0.35 | +2.94% | 146,449 |
| 06/24/06 | 0.34 | +3.03% | 174,906 |
| 03/24/03 | 0.33 | +1.54% | 27,335 |
| 02/24/02 | 0.325 | +4.84% | 45,350 |
| 01/24/01 | 0.31 | -3.13% | 4,776 |
Delayed Quote Canadian Securities Exchange, May 08, 2024 at 01:29 am IST
More quotes
Optimi Health Corp. is an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes, psychedelic substances, such as 3,4-Methylenedioxymethamphetamine (MDMA), natural Manufacturing Practices (GMP)-grade psilocybin, as well as functional mushrooms that focus on the health and wellness markets. The Company produces scalable psychedelic formulations for transformational human experiences. Its products are grown and manufactured at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia. It is a supplier of drug and nutraceutical products. The Company works with customers, health food distributors, and drug developers, and patients regulated by Health Canada.
Sector
Other Specialty Retailers
Calendar
22/05/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +42.86% | 22.17M | |
| -.--% | 843M | |
| -2.36% | 661M | |
| +12.12% | 403M | |
| +33.72% | 248M | |
| 0.00% | 137M | |
| +117.39% | 59.93M |
- Stock Market
- Equities
- OPTI Stock